The activity and sterility of reconstituted alteplase solution and the effectiveness of an alteplase dose-escalation protocol for the clearance of midlinecatheter and central-venous-access device ...

Researchers found that the percentage of patients with functional independence at 90 days was higher in the alteplase group vs the standard treatment group. HealthDay News — For patients with ...

Boehringer Ingelheim's latecomer antibody therapy for COVID-19 has been side-lined, as the company focuses its attention on its thrombolytic drug alteplase, heading into a phase 3 programme later ...

Intravenous alteplase (recombinant tissue plasminogen activator) is restricted for use within 3 h from stroke onset by marketing authorizations. Some patients are treated beyond this approved time ...

MONDAY, March 24, 2025 (HealthDay News) -- For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness and safety outcomes ...

The fibrinolytic activity of alteplase remained at >90% (compared with the standard solution) for the initial 48 hours at 2 °C, regardless of whether the solution had first been frozen (Table 1).